Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyPeach State Health Plan Dupilumab Coverage Update …
    Ask Trek AI about this page
    ModifiedPeach State Health PlanPolicy GA.PMN.32

    Dupilumab (Dupixent)

    Customize your policy alerts

    Sign up for Peach State Health Plan Policy GA.PMN.32 alerts

    Get alerted when Policy GA.PMN.32 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, dosing limits, prescriber qualifications, and approval durations for Dupilumab (Dupixent) across FDA‑approved and selected off‑label indications for Peach State Health Plan Medicaid members.

    Policy Summary
    PayerPeach State Health Plan
    PolicyDupilumab (Dupixent) - Clinical Policy (coverage criteria)
    Policy CodePolicy GA.PMN.32
    Change TypeMultiple material revisions and added indications (CSU, BP, COPD)approval duration extended to 12 months
    Effective DateJul 24, 2024
    Next Review DateFeb 1, 2026
    Key ActionSubmit prior authorization with documentation of diagnosis, prescriber specialty, prior therapy failures, and dosing within policy limits.
    SourceLink
    POLICY UPDATE CHANGES

    Changed Atopic Dermatitis initial criteria from requiring 2 TCS to One TCS.

    Changed CRSwNP initial criteria from requiring two intranasal corticosteroids to one intranasal corticosteroid.

    Changed Prurigo Nodularis criteria from requiring both WI-NRS and total lesion count to requiring one or the other.

    Updated approved indication to include pediatric patients aged 12 years and older for CRSwNP.

    Added newly approved COPD indication to criteria.

    For prurigo nodularis, updated itch scale language to 'Numeric rating scale > 7 (0–10) (e.g., Peak Pruritus NRS)'.

    Added new indication for CSU per updated prescribing information.

    For COPD, revised postbronchodilator FEV1 requirement from 30-70% to 20-80% to align with Nucala.

    Added new indication for bullous pemphigoid (BP) per updated prescribing information and P&T-approved clinical guidance.

    Extended initial approval duration from 6 to 12 months for all labeled indications as maintenance therapy for chronic conditions.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthstypical approval duration
    ≥6 monthsminimum age (AD)
    PDC ≥0.8adherence threshold (asthma)
    No concurrent biologic/JAKconcurrent therapy exclusion
    CSU, BP, COPDindication updates
    ~20+topical corticosteroid mentions

    Coverage Criteria and Indication-Specific Requirements

    Initial Therapy - Atopic Dermatitis

    Covered when ALL of the following are met

    Atopic Dermatitis initial criteria: 1. Diagnosis of atopic dermatitis affecting either ≥10% body surface area (BSA) or involvement of hands/feet/face/neck/scalp/genitals/intertriginous areas; 2. Prescribed by or in consultation with a dermatologist or allergist; 3. Age ≥ 6 months; 4. Failure of both: (a) one formulary medium‑ to very‑high‑potency topical corticosteroid used ≥2 weeks; and (b) one non‑steroidal topical therapy used ≥4 weeks (e.g., topical calcineurin inhibitor such as tacrolimus or pimecrolimus, or crisaborole); 5. Dupixent is not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; 6. Dose does not exceed the age/weight‑specific limits listed in policy (see dosing table: age/weight loading and maintenance doses).

    Dose table provided in policy.

    Initial Therapy - Asthma

    Covered when ALL of the following are met

    Asthma initial criteria: 1. Diagnosis of asthma and one of: (a) absolute blood eosinophils ≥150 cells/mcL within past 3 months; or (b) currently receiving maintenance systemic glucocorticoids for ≥4 weeks; 2. Prescribed by or in consultation with an allergist, immunologist, or pulmonologist; 3. Age ≥ 6 years; 4. ≥2 exacerbations in last 12 months requiring systemic corticosteroids or urgent care/ER/hospital despite adherent controller therapy (medium‑ to high‑dose ICS plus LABA, or LTRA if LABA contraindicated); 5. Dupixent is prescribed concurrently with an ICS plus either a LABA or LTRA; 6. Dupixent is not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; 7. Dose does not exceed the indication‑specific limits (initial one‑time dose for age ≥12 years = 600 mg; maintenance per age/weight).≥ 150 cells/mcL

    Adherence to controller therapy and exacerbation documentation required.

    Initial Therapy - Eosinophilic Esophagitis

    Covered when ALL of the following are met

    EoE initial criteria: 1. Diagnosis of eosinophilic esophagitis confirmed by ≥15 intraepithelial eosinophils per high‑power field on endoscopic biopsy; 2. Prescribed by or in consultation with an allergist, immunologist, or gastroenterologist; 3. Age ≥ 1 year; 4. Weight ≥ 15 kg; 5. Member does not have hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis; 6. Failure of one of: (a) proton pump inhibitor or (b) corticosteroid, unless contraindicated; 7. Dupixent is not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; 8. Dose by weight categories does not exceed specified regimens (200 mg Q2W for 15–<30 kg; 300 mg Q2W for 30–<40 kg; 300 mg QW for ≥40 kg).≥ 15 eos/hpf

    Weight‑based dosing specified.

    Initial Therapy - Chronic Spontaneous Urticaria

    Covered when ALL of the following are met

    CSU initial criteria: 1. Diagnosis of chronic spontaneous urticaria; 2. Prescribed by or in consultation with a dermatologist, immunologist, or allergist; 3. Age ≥ 12 years; 4. Failure of both: (a) two antihistamines (including one second‑generation) at maximum doses each for ≥2 weeks; and (b) a leukotriene receptor antagonist in combination with an antihistamine at maximum doses for ≥2 weeks; 5. Member has not received prior anti‑IgE treatment (e.g., omalizumab) for CSU; 6. Dupixent is not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; 7. Dose does not exceed indication‑specific initial and maintenance dosing by age/weight (e.g., adult initial 600 mg then 300 mg Q2W; adolescent weight‑banded dosing).

    Prior anti‑IgE for CSU excludes Dupixent use per policy.

    Continued Therapy - Atopic Dermatitis

    Covered when ALL of the following are met

    Atopic Dermatitis continued therapy: 1. Member is currently receiving medication via Centene benefit or has previously met initial approval criteria OR member is enrolled in continuity‑of‑care; 2. Member is responding positively to therapy (e.g., reduction in itching/scratching); 3. Dupixent is not prescribed concurrently with another biologic immunomodulator or a JAK inhibitor; 4. If request is for a dose increase, new dose does not exceed the age/weight‑specific maxima listed (see dosing table: adult and pediatric bands).

    Dose caps repeated for continuation requests.

    Other diagnoses/indications

    Other diagnoses/indications handling: If drug had a recent label change not yet reflected in policy, follow the no‑coverage or non‑formulary policies as applicable; if the requested use is not listed in Section III and criterion 1 doesn't apply, refer to the off‑label use policy for the relevant line of business (commercial or Medicaid).

    Refer to CP.CPA.09 (commercial) or CP.PMN.53/CP.PMN.255/CP.PMN.16 (Medicaid) as appropriate.

    Indication-aligned coverage

    Covered when dosing and indication align with prescribing information and patient meets indication-specific criteria per supporting guidance

    Atopic dermatitis dosing: Patient has moderate‑to‑severe atopic dermatitis and prescribed Dupixent dosing matches prescribing information (e.g., adults: 300 mg SC every other week; pediatric weight‑band dosing as specified).dose matches prescribing info

    SOLO trials referenced for outcomes; see Appendix dosing table.

    Asthma dosing: Patient has moderate‑to‑severe asthma and dosing matches age/weight‑specific regimens including loading and maintenance doses per prescribing information (pediatric and adult bands).age/weight‑specific regimen

    GINA referenced in policy background.

    CSU dosing: Patient meets CSU eligibility and dosing aligns with specified regimen (initial 600 mg SC then 300 mg SC every other week for adults; adolescent weight‑banded dosing per policy).

    Summary of coverage criteria changes and new indications

    Policy-level changes and added indications summarized below

    Indication updates: Added COPD, CSU, and bullous pemphigoid indications; expanded CRSwNP pediatric approval to ≥12 years; extended initial approval duration to 12 months for maintenance therapy across labeled indications.

    Recorded RT4 and P&T updates.

    Prior therapy requirement revisions: Atopic dermatitis initial criteria changed from requiring 2 topical corticosteroid trials to 1; CRSwNP initial criteria changed from requiring two intranasal corticosteroid trials to one; Prurigo Nodularis criteria modified to require either numeric itch >7 OR lesion count (previously required both).

    Changes per Department of Community Health alignment.

    COPD lung function revision: Postbronchodilator FEV1 requirement revised from 30–70% to 20–80% predicted for COPD indication to align with comparator criteria.FEV1 20%–80% postbronchodilator

    Per SDC.

    The policy explicitly states that Dupixent is not indicated for the relief of acute bronchospasm or status asthmaticus. Requests for use solely to treat acute bronchospasm or status asthmaticus are outside the labeled indications and are not supported by this clinical policy.

    Requests for Dupixent to treat acute bronchospasm or status asthmaticus are not authorized under this policy. Non‑FDA approved (off‑label) indications are also not addressed unless the prescriber supplies sufficient supporting documentation in accordance with the applicable off‑label use policies (CP.CPA.09 for commercial or CP.PMN.53 for Medicaid). Failure to provide adequate off‑label evidence may result in denial.

    In the extracted text window there are no explicit coverage exclusions listed beyond general product and comparator listings; the content in this section primarily enumerates topical corticosteroid products and formulation notes rather than formal exclusion language.

    This fragment does not contain explicit coverage exclusion statements. The material lists medium‑potency topical corticosteroid products and dosing descriptors; it does not define policy exclusions in this excerpt.

    The fragmented section references topical agents and dose limits but does not articulate explicit coverage exclusions. The text appears to be a formulary/therapeutic alternatives listing rather than exclusionary policy language.

    Known hypersensitivity to Dupixent or any of its excipients is an explicit contraindication and therefore an exclusion for therapy under this policy. Requests for Dupixent for members with documented hypersensitivity to the product or its excipients should be denied.

    For Medicaid members, state Medicaid coverage provisions take precedence where they conflict with this clinical policy. Providers should consult the applicable state Medicaid manual when state rules differ from this policy.

    There are no statements within these chunks designating any conditions as 'not medically necessary.' The excerpted text focuses on listing topical corticosteroid products and dosing information rather than making 'not medically necessary' determinations.

    No 'not medically necessary' conclusions are present in this portion of the document. The content lists medium‑potency topical corticosteroids and associated dosing phrases without declaring items as not medically necessary.

    The provided text fragments do not include 'not medically necessary' statements. They contain repeated listings of topical corticosteroid formulations, application frequency guidance (e.g., apply topically BID), and references to dose limits labeled as 'Varies,' but no formal not‑medically‑necessary rulings are stated in these excerpts.

    Product Strengths, Codes, and Key Numeric Criteria

    Product strengths (NDC-level strengths noted)NDC
    200 mg/1.14 mLDupixent pre-filled syringe or pen strength
    300 mg/2 mLDupixent pre-filled syringe or pen strength
    Coding references (informational)HCPCS
    C9399Unclassified drugs or biologicals
    J3590Unclassified drugs or biologicals
    Absolute blood eosinophil count for asthma
    Asthma absolute eosinophil threshold>= 150 cells/mcL (absolute blood eosinophil count within past 3 months)
    Alternate asthma criterionOr current maintenance systemic glucocorticoids for >= 4 weeks (alternative to eosinophil threshold)
    Timeframe for lab resultEosinophil count must be within the past 3 months
    Eosinophil count for COPD phenotype
    COPD eosinophil phenotype threshold>= 300 cells/µL (blood eosinophil count)
    Age requirementMember must be >= 18 years

    Prior Authorization, Documentation, and Operational Notes

    Prior Authorization

    Prior authorization required with supporting documentation

    Prior authorization is required. Submission must include documentation demonstrating the member's diagnosis, the prescriber specialty or consultation, documentation of required prior therapy failures, and that recommended dosing does not exceed the indication‑specific limits listed in the policy.

    • Diagnosis and supporting clinical notes (office chart notes, labs, etc.)
    • Prescriber is the required specialist or consultation documentation (e.g., dermatologist, allergist, pulmonologist, ENT, gastroenterologist, oncologist as applicable)
    • Evidence of required prior therapy failures per indication
    • Dosing information showing dose is within the policy's age/weight-specific limits
    Prior Authorization

    Indication‑specific prior authorization requirements

    The prior authorization must demonstrate that the request meets the indication‑specific criteria (including continuity-of-care or prior approval status), show evidence of positive response for continuation requests where applicable, confirm absence of concurrent biologic or JAK therapy, and adhere to the policy's dosing limits.

    Background and Scope

    Dupilumab (Dupixent) is an interleukin‑4 receptor alpha antagonist with multiple FDA‑approved indications across dermatologic, respiratory, and eosinophilic disorders, including atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo nodularis, COPD with an eosinophilic phenotype, chronic spontaneous urticaria, and bullous pemphigoid.

    Dupilumab (Dupixent)
    DefinitionDupilumab (Dupixent) is an interleukin-4 receptor alpha antagonist
    Indications overviewMultiple FDA-approved indications across dermatologic, respiratory, and eosinophilic disorders (e.g., AD, asthma, CRSwNP, EoE, PN, COPD, CSU, BP)
    Typical approval durationPolicy specifies initial approval duration of 12 months for labeled indications
    PDC (Proportion of Days Covered)
    PDC definitionProportion of Days Covered (PDC) = sum of days covered in a time frame divided by number of days in the time frame

    Policy Updates and Material Changes

    2024-07-24criteria_revision

    Reduced required topical/intranasal corticosteroid trials: atopic dermatitis initial criteria changed from requiring two topical corticosteroids to one; CRSwNP initial criteria changed from requiring two intranasal corticosteroid trials to one; prurigo nodularis criteria changed to require either a numeric itch rating >7 or total lesion count instead of both.

    2025-01-25criteria_revision

    Updated prurigo nodularis itch scale language and added requirement for no response to 1 month of gabapentinoid therapy for severe immunotherapy-related pruritus; removed requirement for increased IgE level.

    2025-06-25
    Policy Summary
    PayerPeach State Health Plan
    PolicyDupilumab (Dupixent) - Clinical Policy (coverage criteria)
    Policy CodePolicy GA.PMN.32
    Change TypeMultiple material revisions and added indications (CSU, BP, COPD)approval duration extended to 12 months
    Effective DateJul 24, 2024
    Next Review DateFeb 1, 2026
    Key ActionSubmit prior authorization with documentation of diagnosis, prescriber specialty, prior therapy failures, and dosing within policy limits.
    SourceLink
    On This Page
    Coverage Criteria and Indication-Specific RequirementsProduct Strengths, Codes, and Key Numeric CriteriaPrior Authorization, Documentation, and Operational NotesBackground and ScopePolicy Updates and Material Changes
    previous antihistamine therapy attempted

    See policy dosing nodes for exact weight bands.

    ContextEosinophilic phenotype requirement is part of COPD initial criteria with exacerbation history and inhaled therapy failure
    EoE histologic requirement
    EoE histologic threshold>= 15 intraepithelial eosinophils per high-power field (eos/hpf) on endoscopic biopsy
    Age/weight baselineIndication applies to patients >= 1 year and weight >= 15 kg
    Prior therapy requirementFailure of PPI or corticosteroid unless contraindicated
    Proportion of Days Covered (PDC) adherence threshold
    PDC adherence thresholdPDC >= 0.8 (demonstrated adherence to asthma controller therapy in the last 6 months)
    Operational definitionPDC of 0.8 equals receiving controller therapy for at least 5 of the last 6 months
    Measure timeframeCalculated over the last 6 months (180 days)
    Application frequency
    Application frequency (topical)Apply topically to the affected area(s) BID (twice daily)
    Formulations referencedCream, ointment, lotion, gel, spray formulations listed for medium-potency topical corticosteroids
    Documentation noteDocumentation should reflect use of listed topical corticosteroid(s) and application frequency if relied on as prior therapy
    Examples of dosing thresholds
    Systemic dosing example - cyclosporineCyclosporine 3-6 mg/kg/day PO divided BID (dose limit: max 300 mg/day)
    Systemic dosing example - methotrexateMethotrexate 7.5-25 mg once weekly (dose limit: max 25 mg/week)
    Inhaled corticosteroid exampleBudesonide (Pulmicort) >200 mcg/day as medium-high dose ICS (dose limits described per product)
    PDC adherence threshold (example)
    PDC example (numeric)PDC >= 0.8 equals 144 days covered of the last 180 days (approximately 5 of the last 6 months)
    PDC calculationPDC = sum of days covered in timeframe divided by number of days in timeframe
    Use caseUsed to demonstrate adherence to asthma controller therapy for continued approval
    • Specify treated indication on the PA submission
    • Provide continuity‑of‑care or prior approval documentation if applicable
    • For continuation: provide objective evidence of positive response (examples in each indication)
    • Confirm patient is not on another biologic immunomodulator or a JAK inhibitor
    • If pediatric, include weight-based dosing details
    Note

    No prior authorization specified in topical listing excerpt

    The provided topical and product listing excerpts do not state any prior authorization requirements for dupilumab or the listed topical agents in these sections.

    • Topical corticosteroid listings in these chunks are informational; no PA steps are specified
    Note

    Medium‑potency topical corticosteroids listed; dosing noted

    Sections enumerate medium‑potency topical corticosteroids and provide application frequency (typically 'Apply topically to the affected area(s) BID'), but do not state prior authorization requirements for these agents in the excerpt.

    • Examples include clocortolone pivalate 0.1% cream, mometasone 0.1% (Elocon), triamcinolone acetonide formulations
    • Dosing instruction repeated as 'Apply topically to the affected area(s) BID' in multiple chunks
    Note

    No PA codes or explicit requirements in this excerpt

    No specific prior authorization billing codes or explicit PA process steps are present in the topical product excerpts provided.

    • Chunks list product names, formulations, and dosing phrases but do not include PA codes or instructions
    Note

    Topical listing without PA instructions

    This section lists topical agents and application instructions without specifying prior authorization requirements.

    • Repeated medium‑potency topical corticosteroid entries with 'Apply topically to the affected area(s) BID' but no PA guidance
    Note

    Topical product listing only; no PA stated

    The excerpt contains only topical agent listings (product names and dosing phrases) and does not indicate prior authorization requirements for those products.

    • Examples: clocortolone pivalate 0.1% cream, desoximetasone, fluocinolone acetonide; dosing frequency noted as BID
    Note

    Medium‑potency topical corticosteroid list with BID dosing

    Medium‑potency topical corticosteroids are repeatedly listed with application frequency (BID) and product examples; these chunks do not include prior authorization code requirements.

    • Product examples include mometasone 0.1% (Elocon), hydrocortisone valerate 0.2%, triamcinolone acetonide
    • Dosing phrase 'Apply topically to the affected area(s) BID' repeated
    Note

    Topical agents and BID application noted; no PA criteria

    Lists topical agents and typical application frequency (BID); the excerpt does not state prior authorization criteria for these topical products.

    • Includes multiple formulations (cream, ointment, lotion, gel, spray) and repeated BID instruction
    Prior Authorization

    Dose limits and dosing regimen may trigger PA review

    References to 'Dose Limit/Maximum Dose' and 'Dosing Regimen' appear in the formulary/therapeutic alternatives tables, indicating that prior authorization review may consider documented dosing and maximum dose adherence when evaluating requests.

    • Therapeutic alternatives list dose limits for systemic and inhaled agents (e.g., cyclosporine max 300 mg/day; methotrexate max 25 mg/week)
    • PA reviewers may check that requested dupilumab dosing does not exceed the policy's indication‑specific dose limits
    Note

    Comparative therapies and dosing listed (no explicit PA triggers)

    The document lists multiple alternative topical, systemic, inhaled, and intranasal therapies with dosing and maximum dose information for use as comparators; these entries do not themselves establish explicit prior authorization triggers for dupilumab.

    • Includes dosing regimens and dose limits for agents used as therapeutic alternatives or comparators
    • No explicit PA trigger language is present in these comparator listings
    Prior Authorization

    PA must state indication and include pediatric weight‑based dosing

    Prior authorization requests must specify the treated indication and, for pediatric patients, provide weight‑based dosing details consistent with the policy's dosing tables.

    • Provide indication being treated on the PA
    • Include pediatric weight and dosing calculations where applicable
    • Reference the policy's initial and maintenance dose tables for the indicated age/weight band
    Billing Rule

    PA and coding: approval duration and informational codes

    Policy revisions extended initial approval duration to 12 months for labeled indications and added new indications (CSU, BP, COPD); coding notes list unclassified drug codes (C9399, J3590) as informational but inclusion of codes does not guarantee coverage.

    • Initial approval duration changed to 12 months for maintenance therapy
    • New indications added include CSU, bullous pemphigoid, and COPD
    • Coding references C9399 and J3590 are informational only
    Step Therapy

    Required documentation of prior therapy failures

    For multiple indications the policy requires documentation of prior therapy failure (for example, topical corticosteroids and non‑steroidal topical therapy for atopic dermatitis; intranasal corticosteroid for CRSwNP; PPI or corticosteroid for EoE).

    • Atopic dermatitis: failure of one medium‑to‑very‑high potency topical corticosteroid ≥2 weeks and one non‑steroidal topical therapy ≥4 weeks
    • CRSwNP: failure of maintenance intranasal corticosteroid ≥4 weeks unless contraindicated
    • EoE: failure of PPI or corticosteroid unless contraindicated
    Step Therapy

    Required prior or concomitant therapy and adherence evidence

    For some indications (e.g., asthma, CRSwNP, atopic dermatitis/prurigo nodularis), the policy requires demonstrated adherence to or trial of specified controller or topical therapies prior to approval or for continuation.

    • Asthma: adherence to ICS+LABA or LTRA evidenced by PDC ≥ 0.8 for last 6 months
    • CRSwNP: demonstrated adherence to an intranasal corticosteroid unless contraindicated
    • Atopic dermatitis/PN: documented trials of listed topical corticosteroids or other topical therapies as specified
    Step Therapy

    No explicit step therapy in topical listings

    No step therapy rules or required trial sequencing are described in the topical corticosteroid listing chunks; these sections serve as background formulary information and potency groupings.

    • Topical steroid names and medium‑potency groupings are listed without an explicit stepwise algorithm
    • Application frequency is frequently shown as BID
    Step Therapy

    Topical excerpts do not define step therapy

    No step therapy or prerequisite therapy sequencing is specified in the provided topical excerpts; repeated listings indicate product examples rather than an authorization sequence.

    • Chunks repeat medium‑potency corticosteroid products and dosing phrases without stepwise requirements
    Step Therapy

    Repeated medium‑potency topical listings; no step therapy

    These topical product sections repeat medium‑potency corticosteroid listings (product names and BID instruction) and do not present explicit step therapy rules.

    • Repeated entries include desoximetasone, fluocinolone acetonide, flurandrenolide, hydrocortisone valerate, mometasone, triamcinolone
    Note

    Topical therapy history may be relevant before advanced therapy

    Medium‑potency topical corticosteroid history may be relevant as background prior therapy before authorizing advanced therapies like dupilumab, but the excerpt does not define an enforced sequence.

    • Multiple topical corticosteroids and dosing regimens are listed as potential prior/concomitant therapies
    Note

    Enumerated comparator therapies and dosing (no step sequence)

    Appendices enumerate topical, systemic, inhaled and intranasal corticosteroids and immunomodulators with dosing regimens and dose limits that are referenced as comparators; these lists do not themselves create explicit step therapy sequences.

    • Includes dosing limits for systemic agents (e.g., cyclosporine, methotrexate) and inhaled controller products
    • Used as therapeutic alternatives and comparator dosing rather than PA step definitions
    Note

    Policy aligns dupilumab as adjunct/later‑line per guidelines

    Guideline language in the policy positions dupilumab as adjunct or later‑line therapy for asthma and CSU, implying expectation of prior standard therapies before dupilumab is used.

    • GINA recommends Dupixent as adjunct for patients ≥6 years with exacerbations despite high‑dose ICS/LABA and eosinophilic biomarkers
    • CSU guidelines still prioritize omalizumab and antihistamine strategies in stepwise algorithms
    Step Therapy

    Step therapy adjustments: reduced prior therapy requirements

    Initial criteria changes include reduction in required prior topical corticosteroid trials for atopic dermatitis and reduction in required intranasal corticosteroid trials for CRSwNP; providers should follow the updated policy when documenting prior therapy attempts.

    • Atopic dermatitis initial criteria changed from requiring 2 topical corticosteroids to 1
    • CRSwNP initial criteria changed from requiring 2 intranasal corticosteroids to 1
    • Prurigo nodularis diagnostic criteria updated (itch scale language adjusted)
    Documentation Required

    Submit clinical documentation supporting criteria — risk of denial if omitted

    Providers must submit supporting documentation (office notes, labs, other clinical information) that the member meets all approval criteria; failure to submit required documentation may result in denial.

    • Office chart notes, relevant laboratory results (e.g., eosinophil counts, biopsy reports), and prior therapy records
    • For off‑label uses, submit supporting literature or guideline documentation when required
    Documentation Required

    Off‑label use: prescriber must provide supporting evidence

    For off‑label requests (such as immunotherapy‑related pruritus), the prescriber must submit supporting evidence that the requested regimen is within FDA maximums or is supported by NCCN/practice guidelines or peer‑reviewed literature.

    • Documentation that regimen is within FDA maximum dosing for any approved indication or is supported by NCCN or peer‑reviewed literature
    • Evidence that the member has received the medication for at least 30 days when continuation is claimed, if applicable
    Documentation Required

    Document topical agent, formulation, and BID application when used as prior therapy

    Documentation should reflect use of the listed topical corticosteroid(s), formulation, and application frequency (the excerpts repeatedly state 'Apply topically to the affected area(s) BID') if relying on topical therapy as prior or concomitant treatment.

    • Specify agent name, strength/formulation, and documented duration of use
    • Document application frequency (BID) when cited as prior therapy
    Documentation Required

    Provide age‑ and weight‑based dosing documentation for pediatric PAs

    Documentation for pediatric patients must support age‑ and weight‑based dosing (e.g., initial loading and maintenance doses for asthma, EoE, and other weight‑based regimens) as required by the policy.

    • Include patient weight and show calculation of loading and maintenance doses per policy tables
    • Ensure requested dose aligns with the weight band dosing limits in the policy
    Denial Risk

    Denial risk: missing supporting documentation

    Failure to submit required supporting documentation (office notes, labs, other clinical information) showing the member meets all approval criteria may result in denial of the request.

    • Missing prior therapy documentation, lack of lab or biopsy confirmation, or absent prescriber consultation notes are common reasons for denial
    Denial Risk

    Denial risk for unauthorized/off‑label indications without supporting evidence

    Requests for non‑FDA approved indications that are not addressed by the policy require sufficient off‑label documentation per the off‑label use policies (CP.CPA.09 commercial; CP.PMN.53 Medicaid); without it, such requests may be denied.

    • Off‑label requests must reference supporting peer‑reviewed literature or NCCN/practice guideline recommendations
    • Refer to the appropriate off‑label policy for the member's line of business
    Denial Risk

    Dose‑limit exceedance may trigger denial

    References to 'Dose Limit/Maximum Dose' are present; requests exceeding the policy's documented dosing limits may trigger review or denial.

    • Examples include systemic agent caps (e.g., cyclosporine max 300 mg/day) and dupilumab indication‑specific dose ceilings (see dosing tables)
    • PA should include justification if proposing a dose above policy limits (off‑label evidence required)
    Denial Risk

    Contraindication: known hypersensitivity will trigger denial

    Known hypersensitivity to dupilumab or any of its excipients is a contraindication; requests for members with this contraindication would be denied.

    • Confirm no documented allergic reaction to Dupixent or its excipients prior to approval
    Billing Rule

    Coding references informational — verify codes before billing

    Coding references included in the policy (e.g., C9399, J3590) are informational only; inclusion or exclusion of codes does not guarantee coverage and providers should verify coding guidance prior to claims submission.

    • C9399 and J3590 are listed as unclassified drug/biologic codes for informational use
    • Providers should reference current professional coding guidance when billing
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    PDC threshold for asthma adherencePDC >= 0.8 in the last 6 months required to demonstrate adherence (at least 5 of last 6 months)
    Numeric example144 days covered out of the last 180 days equals PDC 0.8
    CRSwNP (abbreviation)
    Abbreviation expansionCRSwNP = chronic rhinosinusitis with nasal polyposis
    ContextUsed throughout policy for the CRSwNP indication and criteria
    Age-related noteDupixent CRSwNP indication includes pediatric patients aged >= 12 years
    Medium Potency Topical Corticosteroids (category)
    Category labelMedium Potency Topical Corticosteroids — category grouping for listed topical steroid agents used as prior/concomitant therapy
    Typical useApplied to affected skin areas, recommended BID (twice daily)
    Dose limitsDose Limit/Maximum Dose entries are listed as 'Varies' for many products in the appendix
    Medium Potency Topical Corticosteroids (group label & context)
    Group label contextSection heading used repeatedly to group specific topical corticosteroid product examples and dosing notes
    Implication for prior therapyListed agents may be documented as prior topical therapy when meeting initial therapy requirements for dermatologic indications
    Application instructionApply topically to the affected area(s) BID as indicated for these products
    Medium Potency Topical Corticosteroids (product examples)
    Product examples (excerpt)Examples include desoximetasone 0.05%/0.25% (Topicort), fluocinolone acetonide 0.025% (Synalar), flurandrenolide 0.05%, hydrocortisone valerate 0.2%, mometasone 0.1% (Elocon), triamcinolone acetonide 0.5% (Aristocort/Kenalog)
    Forms listedCream, ointment, gel, lotion, spray formulations are referenced for these agents
    Dose descriptorDosing regimen lines often indicate 'Apply topically to the affected area(s) BID' and dose limits listed as 'Varies'
    Medium Potency Topical Corticosteroids (heading)
    Repeated heading'Medium Potency Topical Corticosteroids' appears repeatedly as a category heading in the appendix listing
    PurposeUsed to identify acceptable topical comparator/prior therapies for dermatologic indications in the policy
    Documentation expectationWhen used to satisfy prior therapy, documentation should reflect product and BID application frequency
    Medium Potency Topical Corticosteroids (description)
    Category descriptionTopical steroid preparations categorized as medium potency for inflammatory skin conditions; examples and formulations provided
    Typical guidanceApply to affected areas BID; forms include cream, ointment, lotion, gel, spray
    Role in policyListed as therapeutic alternatives and prior therapy options in appendices
    Medium Potency Topical Corticosteroids (examples & forms)
    Examples and formsListed examples include Topicort (desoximetasone), Synalar (fluocinolone acetonide), Cordran (flurandrenolide), Elocon (mometasone), Aristocort/Kenalog (triamcinolone acetonide) in cream/ointment/gel/lotion/spray forms
    Dose limits notationDose Limit/Maximum Dose frequently annotated as 'Varies' in the appendix
    Application frequencyApply topically to affected area(s) BID noted repeatedly with these examples
    BID (definition)
    BID definitionBID = twice daily (appears repeatedly as dosing frequency for topical agents)
    Usage contextUsed in dosing instructions 'Apply topically to the affected area(s) BID' for medium-potency topical corticosteroids
    CommonalityBID is the typical application frequency shown repeatedly across product listings
    Apply topically to the affected area(s)
    Application instructionApply topically to the affected area(s) BID (instruction repeated for topical corticosteroid products)
    ContextIncluded in appendix dosing regimen lines for medium-potency topical corticosteroids
    Documentation relevanceShould be documented when relying on topical therapy as prior treatment in eligibility criteria
    Topical corticosteroids (formulations & description)
    Formulations and general descriptionTopical corticosteroids listed in multiple formulations (cream, ointment, lotion, gel, spray) and concentrations for dermatologic use
    Role in therapyPresented as therapeutic alternatives and prior therapy options within the policy appendices
    Application frequencyTypically applied BID according to appendix dosing lines
    CSU (Chronic Spontaneous Urticaria)
    CSU definitionChronic Spontaneous Urticaria (CSU): spontaneous onset of wheals, angioedema, or both, for more than 6 weeks due to an unknown cause
    Indication contextDupilumab indicated for CSU in patients aged >=12 years who remain symptomatic despite H1 antihistamine treatment
    Clinical evidence noteClinical studies showed dupilumab improved signs/symptoms in patients symptomatic despite H1-antihistamines
    NCCN pruritus grading
    NCCN pruritus gradingG1: mild/localized; G2: moderate (limiting instrumental ADLs); G3: severe (limiting self-care ADLs or sleep)
    Use in policyGrades used for assessment of immunotherapy-related pruritus and treatment decisions per appendix guidance
    Related bullous dermatitis gradingSeparate NCCN grading provided for bullous dermatitis (G1–G4) in appendix
    Abbreviations list
    Common abbreviationsCRSwNP, EoE, PN, COPD, CSU, BP — used throughout policy to denote respective indications
    CRSwNP expansionChronic rhinosinusitis with nasal polyposis (CRSwNP)
    EoE expansionEosinophilic esophagitis (EoE)
    addition

    Added COPD indication and expanded CRSwNP pediatric approval to include patients aged ≥12 years; administrative references and literature reviewed (3Q 2025 annual review recorded).

    2025-09-25addition_and_revision

    Added new indication for chronic spontaneous urticaria (CSU) and revised COPD postbronchodilator FEV1 requirement from 30–70% to 20–80% to align with comparable biologic criteria per SDC.

    2025-12-01addition

    Added bullous pemphigoid (BP) as a covered indication per updated prescribing information and P&T guidance; removed a no-longer-available 100 mg/0.67 mL pre-filled syringe product listing.

    2026-02approval_duration_changeLatest

    Extended initial approval duration from 6 to 12 months for all labeled indications to reflect maintenance therapy for chronic conditions; added diagnostic confirmation requirement for BP and revised immunotherapy-related toxicity options per NCCN guidance.

    Coding lists and HCPCS/NDC references included in the policy are informational only: the inclusion or exclusion of any codes does not guarantee coverage. Providers should verify current professional coding guidance before submitting claims.